Across TCGA pan-cancer cohorts, TRIM15 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TRIM15 data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRIM15 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRIM15 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC and CCRCC are the cancer types where TRIM15 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.915	0.446	.017	14	view →
CCRCC	DFS	Median	IV	0.262	0.908	.022	10	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TRIM15 tumor-vs-normal RNA expression · all TRIM15 data types